JO
APRE icon

John Overdeck’s Aprea Therapeutics APRE Stock Holding History

John Overdeck’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-842
Closed -$11K – 2788
2022
Q3 		$11K Sell
842
-2,177
-72% -$38.6K ﹤0.01% 2412
2022
Q2 		$45K Buy
3,019
+2,088
+224% +$48.1K ﹤0.01% 2355
2022
Q1 		$35K Buy
+931
New +$38.2K ﹤0.01% 2509
2021
Q2 		– Sell
-16,168
Closed -$1.65M – 4020
2021
Q1 		$1.65M Buy
16,168
+8,227
+104% +$960K ﹤0.01% 1864
2020
Q4 		$781K Buy
+7,941
New +$3.78M ﹤0.01% 2191

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's APRE Position: Q4 2022 in Review

John Overdeck sold out of Aprea Therapeutics (APRE) in Q4 2022, closing a stake of 842 shares — an estimated $11K sold.

John Overdeck first reported a position in APRE in Q4 2020 and held it in 5 quarters. The position peaked at $1.65M in Q1 2021. 24 funds tracked by Wall St. Rank hold APRE as of Q4 2022.

  • John Overdeck reported no remaining Aprea Therapeutics position as of Q4 2022 after selling out during the quarter.
  • John Overdeck sold 842 Aprea Therapeutics shares in Q4 2022, an estimated $11K.
  • John Overdeck first reported a position in Aprea Therapeutics in Q4 2020 and held it in 5 quarters.
  • John Overdeck's Aprea Therapeutics position peaked at $1.65M in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.